Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2016

12.09.2016 | Original Article – Clinical Oncology

A let-7 microRNA binding site polymorphism in the KRAS 3′UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population

verfasst von: Hasan Raza Kazmi, Abhijit Chandra, Saket Kumar, Leena Khare Satyam, Annapurna Gupta, Jaya Nigam, Meenu Srivastava, Balraj Mittal

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gallbladder cancer is a lethal malignancy of hepato-biliary system with high incidence in North India, especially along gangetic plain. The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3′ untranslated region (rs61764370, T/G) of KRAS leads to its higher expression. This polymorphism is known to be associated with increased risk and prognosis of various cancers but its association with gallbladder cancer has not been evaluated. To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.

Methods

In present case–control study, we enrolled 541 patients with gallbladder malignancy and 307 controls. Genomic DNA was obtained from peripheral blood and genotyping was performed using Taqman allelic discrimination assay.

Results

Heterozygous (TG) individuals are at a significant higher risk for GBC as compared with wild genotype (TT) (p = 0.007, odds ratio = 2.56, 95 % CI 1.27–5.18). At allelic level, allele G has significant higher risk for GBC as compared with T allele (p = 0.008, odds ratio = 2.5, 95 % CI 1.25–5.01). Survival analysis reveals decrease in overall survival for heterozygous genotype (p < 0.0001, hazard ratio = 3.42, 95 % CI 1.21–4.20). Also, significant decrease in overall survival was observed for patient carrying allele G (p < 0.0001, HR = 2.89, 95 % CI 1.21–4.20) as compared with allele C.

Conclusions

We conclude that KRAS rs61764370 polymorphism is significantly associated with risk and prognosis of gallbladder malignancy in this endemic belt.
Literatur
Zurück zum Zitat Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M (2012) KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res 2(3):298–308PubMedPubMedCentral Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M (2012) KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res 2(3):298–308PubMedPubMedCentral
Zurück zum Zitat Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68(20):8535–8540CrossRefPubMedPubMedCentral Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68(20):8535–8540CrossRefPubMedPubMedCentral
Zurück zum Zitat Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT (2009) A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30(6):1003–1007CrossRefPubMedPubMedCentral Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT (2009) A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30(6):1003–1007CrossRefPubMedPubMedCentral
Zurück zum Zitat Cipollini M, Landi S, Gemignani F (2014) MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Personal Med 7:173–191 Cipollini M, Landi S, Gemignani F (2014) MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Personal Med 7:173–191
Zurück zum Zitat Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH (2015) KRAS polymorphisms are associated with survival of CRC in Chinese population. Tumour Biol 37(4):4727–4734CrossRefPubMed Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH (2015) KRAS polymorphisms are associated with survival of CRC in Chinese population. Tumour Biol 37(4):4727–4734CrossRefPubMed
Zurück zum Zitat Dhir V, Mohandas KM (1999) Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 18(1):24–28PubMed Dhir V, Mohandas KM (1999) Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 18(1):24–28PubMed
Zurück zum Zitat Dutta U (2012) Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 27(4):642–653CrossRefPubMed Dutta U (2012) Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 27(4):642–653CrossRefPubMed
Zurück zum Zitat Ganzinelli M, Rulli E, Caiola E, Chiara Garassino M, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Agnese Fabbri M, Martelli O, Fagnani D, Cristina Locatelli M, Bertolini A, Valmadre G, Pavese Calcagno A, Giuseppa Sarobba M, Marabese M (2015) Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep 5:16331. doi:10.1038/srep16331 CrossRefPubMedPubMedCentral Ganzinelli M, Rulli E, Caiola E, Chiara Garassino M, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Agnese Fabbri M, Martelli O, Fagnani D, Cristina Locatelli M, Bertolini A, Valmadre G, Pavese Calcagno A, Giuseppa Sarobba M, Marabese M (2015) Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep 5:16331. doi:10.​1038/​srep16331 CrossRefPubMedPubMedCentral
Zurück zum Zitat Gupta S, Kori C, Kumar V, Misra S, Akhtar N (2016) Epidemiological study of gallbladder cancer patients from North Indian Gangetic Planes—a high-volume centre’s experience. J Gastrointest Cancer 47(1):27–35CrossRefPubMed Gupta S, Kori C, Kumar V, Misra S, Akhtar N (2016) Epidemiological study of gallbladder cancer patients from North Indian Gangetic Planes—a high-volume centre’s experience. J Gastrointest Cancer 47(1):27–35CrossRefPubMed
Zurück zum Zitat Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB (2011) Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat 128(1):79–84CrossRefPubMed Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB (2011) Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat 128(1):79–84CrossRefPubMed
Zurück zum Zitat Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635–647CrossRefPubMed Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635–647CrossRefPubMed
Zurück zum Zitat Kazmi HR, Chandra A, Baghel K, Singh A, Nigam J, Parmar D, Mahdi AA, Goel SK, Kumar S (2014) Differential expression of cholecystokinin A receptor in gallbladder cancer in the young and elderly suggests two subsets of the same disease? Biomed Res Int 2014:625695CrossRefPubMedPubMedCentral Kazmi HR, Chandra A, Baghel K, Singh A, Nigam J, Parmar D, Mahdi AA, Goel SK, Kumar S (2014) Differential expression of cholecystokinin A receptor in gallbladder cancer in the young and elderly suggests two subsets of the same disease? Biomed Res Int 2014:625695CrossRefPubMedPubMedCentral
Zurück zum Zitat Manoharan N, Tyagi BB, Raina V (2010) Cancer incidences in rural Delhi—2004-05. Asian Pac J Cancer Prev 11(1):73–77PubMed Manoharan N, Tyagi BB, Raina V (2010) Cancer incidences in rural Delhi—2004-05. Asian Pac J Cancer Prev 11(1):73–77PubMed
Zurück zum Zitat Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT (2010) KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69(1):51–53CrossRefPubMed Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT (2010) KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69(1):51–53CrossRefPubMed
Zurück zum Zitat Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA et al (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141(2):386–401CrossRef Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA et al (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141(2):386–401CrossRef
Zurück zum Zitat Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J (2011) A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12(4):377–386CrossRefPubMedPubMedCentral Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J (2011) A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12(4):377–386CrossRefPubMedPubMedCentral
Zurück zum Zitat Pelletier C, Weidhaas JB (2010) MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn 10(6):817–829CrossRefPubMed Pelletier C, Weidhaas JB (2010) MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn 10(6):817–829CrossRefPubMed
Zurück zum Zitat Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP (2012) The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS ONE 7(5):e37891CrossRefPubMedPubMedCentral Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP (2012) The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS ONE 7(5):e37891CrossRefPubMedPubMedCentral
Zurück zum Zitat Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB (2010) A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 70(16):6509–6515CrossRefPubMedPubMedCentral Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB (2010) A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 70(16):6509–6515CrossRefPubMedPubMedCentral
Zurück zum Zitat Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M (2013) The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genom 23(3):142–147CrossRef Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M (2013) The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genom 23(3):142–147CrossRef
Zurück zum Zitat Shaffer EA (2008) Gallbladder cancer: the basics. Gastroenterol Hepatol (NY) 4(10):737–741 Shaffer EA (2008) Gallbladder cancer: the basics. Gastroenterol Hepatol (NY) 4(10):737–741
Zurück zum Zitat Yadav A, Gupta A, Yadav S, Rastogi N, Agrawal S, Kumar A, Kumar V, Misra S, Mittal B (2015) Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival. Tumour Biol 37(6):8083–8095CrossRefPubMed Yadav A, Gupta A, Yadav S, Rastogi N, Agrawal S, Kumar A, Kumar V, Misra S, Mittal B (2015) Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival. Tumour Biol 37(6):8083–8095CrossRefPubMed
Metadaten
Titel
A let-7 microRNA binding site polymorphism in the KRAS 3′UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population
verfasst von
Hasan Raza Kazmi
Abhijit Chandra
Saket Kumar
Leena Khare Satyam
Annapurna Gupta
Jaya Nigam
Meenu Srivastava
Balraj Mittal
Publikationsdatum
12.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2254-9

Weitere Artikel der Ausgabe 12/2016

Journal of Cancer Research and Clinical Oncology 12/2016 Zur Ausgabe

Acknowledgement to Reviewers

Reviewer Acknowledgements 2015

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.